Ropes & Gray represented Viridian Therapeutics, Inc. in the offering, and Wilmer Cutler Pickering Hale and Dorr represented the underwriters. Viridian Therapeutics, Inc. (Nasdaq: VRDN), a...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented the underwriters. Kymera Therapeutics, Inc. (Nasdaq: KYMR) (Kymera), a clinical-stage biopharmaceutical company, announced its public offering of 2,830,533 shares...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Disc Medicine, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriter. Disc Medicine, Inc. (Nasdaq: IRON) (“Disc”) announced...
You must be a Standard 1 Year member to access this content.
Osler, Hoskin & Harcourt acted as Canadian counsel to Milestone Pharmaceuticals Inc. in the offering, Cooleyacted as US counsel to the company. Wilmer Cutler Pickering Hale...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Kymera Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Kymera Therapeutics, Inc. (Nasdaq: KYMR) (“Kymera”) announced its...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler advised Celldex Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Celldex Therapeutics, Inc. (Nasdaq: CLDX) (“Celldex”) announced the...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Crescera Capital Acquisition Corp. on the deal while Wilmer Cutler Pickering Hale and Dorr represented the underwriter. Crescera Capital Acquisition Corp. executed its...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer...
You must be a Standard 1 Year member to access this content.
